Klingel acquires MedTech companies Bächler Feintech and Gehring Cut with the support of IK Investment Partners

ik-investment-partners

Klingel medical metal group (“Klingel”), owned by the IK VIII Fund, announce that it has completed the acquisitions of Bächler Feintech AG (“Bächler”) and Gehring Cut AG (“Gehring”). Both companies are leading manufacturers of high-precision surgical instruments for the global MedTech market.

Bächler was founded in 1964 and employs 140 people at the production site in Hölstein, Switzerland, where state-of-the-art machinery and industry-leading quality management are established.

Gehring was founded in 1948 and employs 75 people at the production site in Matzingen, Switzerland, where similar to Bächler, a state-of-the-art machine park and industry-leading quality management are established.

Through these acquisitions, Klingel strengthens its position as the leading pan-European MedTech CMO for complex components and instruments. The extended platform enables the combined group to provide its broad global customer base with a more flexible service to meet their customers’ high quality requirements and to serve their ever-increasing demands.

“With Bächler and Gehring we have found the perfect complements to our MedTech platform. Through the acquisitions, we are gaining additional blue-chip customers, manufacturing capabilities and valuable expertise for our group, enabling us to create real value-add for our customers. In addition, we have found strong partners in the management teams of Bächler and Gehring and look forward to our next phase of growth as a larger pan-European group”, said Ralf Petrawitz, CEO of Klingel.

For further questions, please contact:

KLINGEL medical metal
Ralf Petrawitz, CEO
Phone: +49 7231 6519 0

IK Investment Partners
Anders Petersson, Partner
Phone: +49 40 369 8850

Mikaela Murekian, Director Communications & ESG
Phone: +44 77 87 573 566
mikaela.murekian@ikinvest.com

About KLINGEL medical metal
For more than 30 years, KLINGEL medical metal GmbH has been one of the leading European precision technology companies with a strategic focus on medical technology industries. Employing over 300 people, KLINGEL medical metal GmbH specialises in the precision processing of materials with low machinability, such as titanium and high-grade stainless steel. KLINGEL offers unrivalled technical quality and aesthetic perfection. For more information, visit www.klingel-med.de

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €10 billion of capital and invested in over 125 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

Press Service

Categories: News

Tags:

GP Bullhound advises Dudnyk on its sale to Fishawack

Gp Bullhound

GP Bullhound acted as exclusive financial advisor to Dudnyk, a Philadelphia-based healthcare marketing communications agency, on its sale to the Fishawack Group of Companies, one of the world’s leading independent healthcare communication specialists, based in Manchester, UK.

Independently owned for the past 25 years, Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients.

Dudnyk President, Christopher Tobias, commented: “By joining forces with Fishawack, Dudnyk will be able to offer clients an even stronger service offering, including expertise in additional verticals like scientific communications and medical education. We are also excited to further expand our global capabilities, both commercially and medically, for our clients who operate on a scale outside of the US.”

Oliver Schweitzer, Executive Director at GP Bullhound, commented: “Dudnyk combines strategic, scientific and highly creative capabilities to bring to market life-changing brands and serve clients in the biotech, pharmaceutical, and medical device industries. We are delighted to have advised Dudnyk and to have helped them find the ideal partner for the next phase of growth.”

The transaction is further testament to GP Bullhound’s expertise in advising category leaders in the Digital and Marketing Services sectors, with more than 20 transactions completed in the last 24 months including the sales of Oliver to You & Mr Jones, Filter to Merkle, Kepler Group to KYU, and Solita to Apax Digital, among many others.

Inquiries
For inquiries please contact: Oliver Schweitzer, Executive Director, at oliver.schweitzer@gpbullhound.com

About GP Bullhound
GP Bullhound is a leading technology advisory and investment firm, providing transaction advice and capital to the world’s best entrepreneurs and founders. Founded in 1999, the firm today has offices in London, San Francisco, Stockholm, Berlin, Manchester, Paris, Hong Kong, Madrid and New York. For more information, please visit www.gpbullhound.com.

Categories: News

Tags:

Gimv sells Oldelft Ultrasound, producer of innovative ultrasonic probes for medical diagnostics

GIMV

In 2012, Gimv acquired a majority stake in medical diagnostics company Oldelft Ultrasound (Delft – NL, www.oldelft.nl), which develops and produces innovative ultrasonic probes for medical diagnosis, with the ambition of achieving further international growth through continuous development and expanding the product portfolio. Oldelft is the only independent player worldwide in the field of specialized TEE (transesophageal echocardiography) probes, serving, among other things, for cardiac imaging via the oesophagus.

Over the past seven years, continuous investment in R&D has further expanded Oldelft’s position as a technology leader in the growing echocardiography market. Leveraging its unique positioning, Oldelft has achieved impressive sales growth and built up an impressive global customer base of tier-1 OEMs in the market for ultrasound medical equipment. Recently a new type of probe, based on matrix/3D technology, has been developed and tested in the market.

Gimv announces today that it has sold on its majority shareholding in Oldelft in a management buy-out supported by Smile Invest.

Rob Smallenburg, CEO Oldelft: We are particularly happy at the support we have received from Gimv over the past 7 years. The good cooperation and Gimv’s knowledge of the field have enabled us to concentrate on Oldelft’s growth. Our continuous focus on innovation has enabled us to distinguish ourselves sustainably from other players. ”

Elderd Land, Partner, Gimv Health & Care platform: ” We look back with pleasure on the successful collaboration between Gimv and Oldelft. The growth figures and the recent development of the new matrix technology underline this success. Gimv is proud to have been to support Oldelf’s further expansion in recent years. Management has done an excellent job in this area. “

The yield on Oldelft over the entire investment period exceeds Gimv’s long-term average. No further financial details, however, are provided on the transaction itself. This transaction has no material impact on the NAV of Gimv.

 

 

Categories: News

Tags:

Nyxoah receives European CE Mark approval for the Genio™ system to treat sleep apnea

GIlde Healthcare

Utrecht, The Netherlands and Mont-Saint-Guibert, Belgium – Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio™ system in Europe. The Genio™ system is the world’s first and only battery-free, leadless and minimally invasive neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation for moderate to severe obstructive sleep apnea (OSA) patients who have failed conventional therapy.

The CE Mark approval was based on the BLAST OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) clinical study, a prospective study that evaluated the safety and performance of the Genio™ system in 7 centers in France and Australia.

“Patients from the BLAST OSA study show a major improvement in their sleep apnea symptoms and their Quality of Life” said Enrique Vega, Chief Executive Officer of Nyxoah.

Robert Taub, Chairman of Nyxoah said: “The sleep community is looking for alternative solutions for OSA patients who refuse currently available therapies or are not compliant. Having now received CE mark, Nyxoah’s Genio™ system is well on its way to fulfil this need”.

About Nyxoah

Nyxoah S.A., headquarted in Mont-Saint-Guibert – Belgium, is a healthtech company focused on the development of innovative, neurostimulation-based solutions and services for sleep related disorders. Nyxoah S.A. was co-founded in 2009 by Robert Taub. For more information, please visit www.nyxoah.com.

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in healthtech and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com

Categories: News

Tags:

EURAZEO CAPITAL enters into exclusive discussions with MONTAGU to acquire DORC

Eurazeo

Paris, March 13, 2019 – Eurazeo Capital entered into exclusive discussions with funds managed by
Montagu Private Equity to acquire DORC (Dutch Ophthalmic Research Center). Eurazeo Capital will invest
close to 300M€ in this transaction. DORC will be the fifth investment of Eurazeo Capital IV. This investment
perfectly fits the strategy presented during the 2018 Annual Results presentation.
Established in 1983 and headquartered in the Netherlands, the company operates in the medical
technology sector and is one of the global leading specialists of vitreoretinal surgery. DORC designs,
manufactures and distributes ophthalmic surgery equipment, consumables and instruments.
The company serves over 5,700 surgeons and is recognized for its strong innovation capability. DORC is
a global company with a presence across 80 countries and enjoys strong market shares in Europe. DORC
has more than 500 employees worldwide.

Additional financial information will be disclosed at the closing of the transaction.
Marc Frappier, Managing Partner, Head of Eurazeo Capital commented: “The acquisition of DORC fits
perfectly with our investment strategy to support growing businesses with a strong international
development potential as they scale up. Widely recognized as innovative and best in class by surgeons
across the world, the Company delivers remarkable financial performance. We expect to leverage our
international network to accelerate DORC’s growth.”

DORC will engage to immediately inform and consult the employee representative bodies of the company.
The final closing of the transaction will occur once the process with employee representative bodies is
finalized and clearance from relevant antitrust authorities is obtained.
About Eurazeo
o Eurazeo is a leading global investment company, with a diversified portfolio of €17 billion in assets under
management, including nearly €11 billion from third parties, invested in over 300 companies. With its considerable
private equity, venture capital, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its 235 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.

Eurazeo has offices in Paris, New York, Sao Paulo, Buenos Aires, Shanghai, London, Luxembourg, Frankfurt and
Madrid.

o Eurazeo is listed on Euronext Paris.
o ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

Categories: News

Tags:

CSAM Announces Deal to Acquire Arcid AS

Priveq

The transaction further strengthens CSAM’s leadership in the Nordic niche eHealth market
OSLO, Norway (March 12th, 2018) – CSAM announced today that it has signed an agreement
to acquire Arcid – a Norwegian eHealth company that focuses on information flow in the
teleradiology domain.

Arcid provides eHealth solutions that improve workflows and simplify the interaction between
healthcare professionals. Among the company’s best-known products are TRIS, a Radiology
Information System; Arcidis, a teleradiology information solution; and HelseMail, a Software as
Service (SaaS) communication platform that enables the encrypted transfer of large, high
volume, and sensitive patient information.

– The combination of CSAM and Arcid will create an innovative and comprehensive offering in
the medical imaging and connected health markets, enabling us to better serve clinicians and
patients, said Sverre Flatby, CSAM CEO. – Arcid has an impressive reputation for delivering
efficiency, quality, and exceptional patient care with their niche software solutions, and we are
pleased they have entrusted CSAM to carry on that tradition of excellence.

– I am confident that CSAM is the right home for Arcid’s team in this exciting growth period to
come, said Kåre-Bjørn Kongsnes, business developer and majority shareholder of Arcid. –
Integrating our highly competent team of people with CSAM, the leading Nordic niche player
within eHealth, strengthens this viable and powerful position.
The acquisition of Arcid is consistent with CSAM’s strategy to pursue growth through a
combination of strategic M&As and organic sales. The transaction is estimated to close before
the end of the month.

– Arcid’s products are an important complement to CSAM’s software solutions in the medical
imaging and connected healthcare domains, strengthening our leadership in these key market
segments, said Flatby. – The mixture of our customers, code and competencies will allow us to
provide even greater value to customers across both public and private healthcare
organisations.

CSAM has been a leading provider of medical imaging and connected healthcare solutions in
the Nordics for more than a decade. The company works closely with healthcare professionals
and organisations to develop software solutions that deliver the highest value for their
operations.

About CSAM
CSAM has established itself as a leading Nordic niche player in the specialised eHealth market
with a unique blend of best-in-class innovative technology, and outstanding human skills. The
company’s diverse portfolio of software solutions enables healthcare providers to access
relevant clinical information at the point of care. CSAM’s commercial headquarters are located
in Oslo, Norway. In addition to the new offices in Tromsø, the company also has local offices in
Stockholm, Karlstad, Gothenburg, Helsinki, Oulu, Tampere, and Warwickshire, as well as a
wholly owned software engineering subsidiary in the Philippines.

A privately-owned company backed by strong financial partners, CSAM aspires to achieve
continued growth both organically and through selected mergers and acquisitions. For more
information, visit www.csamhealth.com.

For more information, please contact:
Sverre Flatby, CEO Jennifer Goode, Communications Director
sverre.flatby@csamhealth.com jennifer.goode@csamhealth.com
+47 9159 9159 +1-705-760-0782
Kåre-Bjørn Kongsnes, Business Developer
kb@kongsnes.no
+47 900 11 040

Categories: News

Tags:

CXA Group Raises US$25 Million to Accelerate Expansion Across Asia-Pacific

Heritas

New investors HSBC, Singtel Innov8, Telkom Indonesia MDI Ventures, Sumitomo Corporation Equity Asia, Muang Thai Fuchsia Ventures, Humanica, Heritas Venture Fund and others join CXA’s latest financing round

This strategic capital will accelerate CXA’s growth momentum in the Asia-Pacific region and reinforce the company’s mission of improving the health and wellness of individuals through its employer-driven population health platform

CXA Group, Asia’s one-stop, predictive and data intelligence platform for better health, wealth and wellness choices, announced today that it has raised US$25 million in its latest round of funding. CXA’s new group of strategic investors include HSBC, Singtel Innov8, Telkom Indonesia MDI Ventures, Sumitomo Corporation Equity Asia, Muang Thai Fuchsia Ventures, Humanica and Heritas Venture Fund, underscoring the company’s aim to be the leading health ecosystem platform addressing escalating healthcare costs across the region.

The investment by these leading global financial services institutions, telecommunications providers and payroll companies reflect their belief in CXA’s long-term growth opportunity, and the company’s unique ability to shift healthcare spend from treatment to prevention, without employers spending more.

Rosaline Chow Koo, Founder and Chief Executive Officer, CXA Group said: “We are honoured to welcome these top-tier corporations into our roster of strategic investors and partners. CXA is today the leading health ecosystem platform that enables individuals across Asia to make better choices for healthier living, starting from the workplace, thereby empowering a shift in spend from treatment to prevention. We have seen overwhelming interest from global strategic investors who are excited to work with us to advance our business and vision.”

“These latest investors will become strategic partners, and we will look to closely collaborate in designing customised platform-led solutions for their B2B enterprise customers, and as importantly, the employees of these enterprises,” said Koo.

With chronic diseases hitting people in Asia earlier than in the West and healthcare costs escalating1, the company found that the antiquated pen-and-paper, one-size-fits-all approach to managing these costs was systemically wrong. This situation, if left unaddressed, would only get worse and become economically unsustainable over time.

The company has pioneered a one-stop, self-service platform that allows employers to give their employees access to an ever-widening range of health, wealth and wellness offerings, personalised based on the individual’s health and life-stage data. Employees can purchase offerings by drawing down on existing insurance policies provided by their employers and using funds that are then released into the platform’s eWallet to make transactions cashless, fast and easy.

Through the aggregation, anonymisation and analysis of digitised health and life-stage data, CXA helps employers get to the root cause of their workforces’ health issues and design specific interventions – such as corporate wellness and disease management initiatives – that will have the greatest impact on cost and health improvement, for reductions in tomorrow’s chronic disease and healthcare spend, today.

Headquartered in Singapore, CXA achieved revenue growth of 65 percent in 2018 and is expected to double that in 2019. This latest funding round follows US$33 million in total funding from Series A and B in 2015 and 2017 respectively. Other investors in CXA include B Capital Group, Openspace Ventures, Government-linked strategic investor EDBI, BioVeda Capital, FengHe Asia, Philips and RGAx.

Supporting Quotes from New Investors:

Edgar Hardless, Chief Executive Officer of Singtel Innov8 said, “CXA’s innovative use of analytics helps its enterprise clients effectively manage their healthcare costs and promote their employees’ wellbeing. We are excited to be an investor in CXA and help with their expansion across Asia.”

“CXA is rapidly emerging as a leader in the Health and Insurtech space. It has an innovative platform-led approach to helping companies optimise their health spend through personalised engagement with employees about their physical and financial wellness. We are excited about this investment partnership and the disruptive opportunities it presents,” said Bryce Johns, Group Head of Insurance, HSBC.

“Heritas invests in high-growth companies that are tackling major healthcare challenges faced by Asian populations,” said Chik Wai Chiew, Executive Director and CEO, Heritas Capital Management. “We are pleased to support CXA in this financing round to scale its employer-driven population health platform, as the company continues to pioneer solutions that connect the whole healthcare continuum and shift employers’ healthcare spend from treatment to prevention.”

Supporting Quotes from Previous Investors:

“Strategic investment in CXA from HSBC, Singtel Innov8 and others reinforces our belief in technology enablement and value creation from high-growth companies partnering with larger organisations and transforming in collaborative fashion. With the collective support of banks, insurers, telcos and payroll companies as co-investors, CXA can now accelerate its expansion into new markets and bancassurance channels, while creating new revenue opportunities for these partners’ businesses,” said Eduardo Saverin, Co-Founder and Partner, B Capital Group, the lead investor in CXA’s previous Series B funding round.

About CXA Group:

CXA Group is Asia’s one-stop, predictive and data intelligence platform for better health, wealth and wellness choices. Through the CXA platform, employers can empower employees with access to personalised health and lifestyle offerings, with clear and quantifiable ROI for the business. Founded in 2013 with the mission of transforming the delivery of employee benefits from pen-and-paper and one-size-fits-all to a digitised and personalised platform, the company aims to shift healthcare spend from treatment to prevention, to improve workplace population health.

Driven by a team of industry veterans with extensive leadership experience across Asia’s human resource, insurance, finance, healthcare and technology industries, CXA serves more than 600 enterprises, including Fortune 500 companies, and more than 400,000 employees in 20 countries. CXA has received recognition as InsurTech of the Year from the Asia Insurance Industry Awards and was among the top three most impactful innovations at the Singapore Digital Techblazer Awards.

CSAM Announces Deal to Acquire Arcid AS

Priveq

The transaction further strengthens CSAM’s leadership in the Nordic niche eHealth market
OSLO, Norway (March 12th, 2018) – CSAM announced today that it has signed an agreement
to acquire Arcid – a Norwegian eHealth company that focuses on information flow in the
teleradiology domain.

Arcid provides eHealth solutions that improve workflows and simplify the interaction between
healthcare professionals. Among the company’s best-known products are TRIS, a Radiology
Information System; Arcidis, a teleradiology information solution; and HelseMail, a Software as
Service (SaaS) communication platform that enables the encrypted transfer of large, high
volume, and sensitive patient information.

– The combination of CSAM and Arcid will create an innovative and comprehensive offering in
the medical imaging and connected health markets, enabling us to better serve clinicians and
patients, said Sverre Flatby, CSAM CEO. – Arcid has an impressive reputation for delivering
efficiency, quality, and exceptional patient care with their niche software solutions, and we are
pleased they have entrusted CSAM to carry on that tradition of excellence.

– I am confident that CSAM is the right home for Arcid’s team in this exciting growth period to
come, said Kåre-Bjørn Kongsnes, business developer and majority shareholder of Arcid. –
Integrating our highly competent team of people with CSAM, the leading Nordic niche player
within eHealth, strengthens this viable and powerful position.
The acquisition of Arcid is consistent with CSAM’s strategy to pursue growth through a
combination of strategic M&As and organic sales. The transaction is estimated to close before
the end of the month.

– Arcid’s products are an important complement to CSAM’s software solutions in the medical
imaging and connected healthcare domains, strengthening our leadership in these key market
segments, said Flatby. – The mixture of our customers, code and competencies will allow us to
provide even greater value to customers across both public and private healthcare
organisations.

CSAM has been a leading provider of medical imaging and connected healthcare solutions in
the Nordics for more than a decade. The company works closely with healthcare professionals
and organisations to develop software solutions that deliver the highest value for their
operations.

About CSAM
CSAM has established itself as a leading Nordic niche player in the specialised eHealth market
with a unique blend of best-in-class innovative technology, and outstanding human skills. The
company’s diverse portfolio of software solutions enables healthcare providers to access
relevant clinical information at the point of care. CSAM’s commercial headquarters are located
in Oslo, Norway. In addition to the new offices in Tromsø, the company also has local offices in
Stockholm, Karlstad, Gothenburg, Helsinki, Oulu, Tampere, and Warwickshire, as well as a
wholly owned software engineering subsidiary in the Philippines.
A privately-owned company backed by strong financial partners, CSAM aspires to achieve
continued growth both organically and through selected mergers and acquisitions. For more
information, visit www.csamhealth.com.

For more information, please contact:
Sverre Flatby, CEO Jennifer Goode, Communications Director
sverre.flatby@csamhealth.com jennifer.goode@csamhealth.com
+47 9159 9159 +1-705-760-0782
Kåre-Bjørn Kongsnes, Business Developer
kb@kongsnes.no
+47 900 11 040

Categories: News

Tags:

CSAM Announces Deal to Acquire Arcid AS

Priveq

The transaction further strengthens CSAM’s leadership in the Nordic niche eHealth market

OSLO, Norway (March 12th, 2018) –CSAM announced today that it has signed an agreement to acquire Arcid –a Norwegian eHealth company that focuses on information flow in the tele radiology domain.

Arcid provides eHealth solutions that improve workflows and simplify the interaction between healthcare professionals. Among the company’s best-known products are TRIS, a Radiology Information System;Arcidis, a teleradiology information solution;and HelseMail, a Software as Service (SaaS) communication platform that enables theencrypted transferof large, high volume, and sensitive patient information.

-The combination of CSAM and Arcid will create an innovative and comprehensive offering in the medical imaging and connected health markets, enabling us to better serve clinicians and patients, said Sverre Flatby, CSAM CEO. –Arcid has an impressive reputation for delivering efficiency, quality, and exceptional patient care with their niche software solutions, and we are pleased they have entrusted CSAM to carry on that tradition of excellence.

-I am confident that CSAM is the right home for Arcid’s team in this exciting growth period to come, said Kåre-Bjørn Kongsnes, business developer and majority shareholder of Arcid. –Integrating our highly competent team of people with CSAM, the leading Nordic niche player within eHealth, strengthens this viable and powerful position.

The acquisition of Arcid is consistent with CSAM’s strategy to pursue growth through a combination of strategic M&As and organic sales. The transaction is estimated to close before the end of the month.

-Arcid’s products are an important complement to CSAM’s software solutions in the medical imaging and connected healthcare domains, strengthening our leadership in these key market segments, said Flatby. -The mixture of our customers, code and competencies will allow us to provide even greater value to customers across both public and private healthcare organisations.

CSAM has been a leading provider of medical imaging and connected healthcare solutions in the Nordics for more than a decade.The company works closely with healthcare professionals and organisations to develop software solutions that deliver the highest value for their operations.

About CSAM

CSAM has established itself as a leading Nordic niche player in the specialised eHealth marketwith a unique blend of best-in-class innovative technology, and outstanding human skills. The company’s diverse portfolio of software solutions enables healthcare providers to access relevant clinical information at the point of care. CSAM’scommercialheadquarters are located in Oslo, Norway. In addition to the new offices in Tromsø, the companyalso has local offices in Stockholm, Karlstad, Gothenburg, Helsinki, Oulu, Tampere, and Warwickshire, as well as a wholly owned software engineering subsidiary in the Philippines.

A privately-owned company backed by strong financial partners, CSAM aspires to achieve continued growth both organically and through selected mergers and acquisitions. For more information, visit www.csamhealth.com.

For more information, please contact:

Sverre Flatby, CEOJennifer Goode, Communications Directorsverre.flatby@csamhealth.comjennifer.goode@csamhealth.com+47 9159 9159+1-705-760-0782Kåre-Bjørn Kongsnes, Business Developerkb@kongsnes.no+47 900 11 040

Categories: News

Tags:

Gilde Healthcare acquires healthcare food supplier Eetgemak from Value8

GIlde Healthcare

Gilde Healthcare’s investment allows Eetgemak to realize new growth plans, including expansion into Belgium

Utrecht and Frankfurt – Gilde Healthcare, the European specialist investor in healthcare, acquires a majority stake in Eetgemak from stock listed investment firm Value8. The acquisition is the first investment in Gilde Healthcare’s new €200 million private equity fund focused on the healthcare industry. Katwijk based Eetgemak is the market leader in chilled meals for Dutch healthcare institutions. With Gilde as a new investor, Eetgemak will further expand its market position by growing in both existing as well as new markets, like Belgium.

Doctors and dietitians increasingly recognize the importance of tasty, healthy food that meets the patient’s wishes in the healing process. At the same time, there is a constant pressure on healthcare institutions to work more efficiently and to provide better care with less staff. With an assortment of thousands of different chilled meals, Eetgemak offers hospitals, care institutions and people at home healthy meals at low prices. Moreover, through its scale and expertise, Eetgemak is able to cater to the many types of dietary needs of patients and residents in care institutions.

The investment in Eetgemak fits well in Gilde Healthcare’s new private equity fund: “We look for companies that contribute to the improvement of care. Moreover, we actively contribute to the development of our portfolio companies through our specific knowledge and experience in the healthcare industry. We are very excited about Eetgemak’s growth opportunities and look forward to a productive collaboration,” says Hugo de Bruin, partner at Gilde Healthcare.

“Gilde’s investment enables us to execute our growth strategy, not only in the Netherlands, but also across the border in Belgium. In addition to accelerating organic growth, we are also interested in new partnerships and potential acquisitions,” says Leo van der Krogt, CEO at Eetgemak.

About Eetgemak

Eetgemak prepares chilled meals for hospitals, home care organizations, care centers, nursing homes, expertise centers, service apartments, living communities, restaurants, caterers, schools and daycare centers. Professional chefs prepare a wide range of seasonal dishes with great pleasure every day. Our motto is ‘everyone joins for dinner’. Whether it’s preference, meal type, consistency or diet; taste and quality are always paramount. Everyone deserves a healthy, fresh and tasty meal. This is why every day we cook fresh and healthy meals with the best ingredients. https://www.eetgemak.nl

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two fund strategies: private equity and venture & growth capital. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies including healthcare providers, suppliers of medical products and service providers, with a primary focus on the Benelux and DACH regions. Gilde Healthcare’s venture & growth fund is focused on fast growing health tech and therapeutics companies based in Europe and North America. https://gildehealthcare.com

 

Media Contacts

Gilde Healthcare

Hugo de Bruin
Partner
Newtonlaan 91
3584BP Utrecht
The Netherlands
debruin@gildehealthcare.com
+31 (0)30 219 2565

Eetgemak

Leo van der Krogt
CEO
Taanderstraat 9a
2222 BG Katwijk
The Netherlands
leo@eetgemak.nl
+31 (0)71 408 4140

Categories: News

Tags: